Related Experiment Video

Updated: May 27, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of

Shi Zhang1, Xi-Jin Wang, Li-Peng Tian

  • 1Department of Neurology & Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai, P.R. China.

Journal of Neuroinflammation
|November 8, 2011
PubMed
Abstract

Insights

Deficits in CD200-CD200R signaling worsen microglial activation and dopaminergic neurodegeneration in a Parkinson's disease rat model. This suggests CD200-CD200R dysfunction contributes to Parkinson's disease pathogenesis.

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Microglial activation is implicated in Parkinson's disease (PD) pathogenesis.
  • CD200-CD200R signaling normally restrains microglial activation.
  • Impaired CD200R expression in PD patients suggests intrinsic signaling abnormalities.

Purpose of the Study:

  • To investigate the in vivo role of CD200-CD200R signaling malfunction in PD pathogenesis.
  • To elucidate how blocking CD200-CD200R interaction affects dopaminergic neurodegeneration and neuroinflammation.

Main Methods:

  • Utilized a 6-hydroxydopamine (6-OHDA) rat model of PD.
  • Administered CD200R-blocking antibody (BAb) to the striatum.
  • Assessed motor deficits, dopaminergic neurodegeneration, microglial activation, and cytokine levels.

Main Results:

  • Blocking CD200-CD200R signaling significantly increased motor deficits and dopaminergic neuron loss.
  • Monoamine levels were markedly decreased in BAb-treated rats.
  • Increased microglial activation and pro-inflammatory cytokines correlated with neurodegeneration.

Conclusions:

  • Deficits in the CD200-CD200R system exacerbate microglial activation and dopaminergic neurodegeneration in a PD rat model.
  • Dysfunction of CD200-CD200R signaling is suggested to be involved in PD aetiopathogenesis.

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.